753.41
3.25%
23.68
Vorhandelsmarkt:
754.65
1.24
+0.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$729.73
Offen:
$735.785
24-Stunden-Volumen:
4.92M
Relative Volume:
1.53
Marktkapitalisierung:
$693.54B
Einnahmen:
$40.86B
Nettoeinkommen (Verlust:
$8.37B
KGV:
139.02
EPS:
5.4193
Netto-Cashflow:
$-2.28B
1W Leistung:
-7.19%
1M Leistung:
-17.93%
6M Leistung:
-3.80%
1J Leistung:
+26.07%
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
LLY | 753.41 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 105.27 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 153.11 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 167.76 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 97.44 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-10-17 | Eingeleitet | Bernstein | Outperform |
2024-09-13 | Fortgesetzt | Citigroup | Buy |
2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-10-20 | Fortgesetzt | UBS | Buy |
2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
2023-07-26 | Bestätigt | Citigroup | Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-24 | Bestätigt | BofA Securities | Buy |
2023-05-24 | Bestätigt | UBS | Buy |
2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-09-22 | Hochstufung | UBS | Neutral → Buy |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
2021-12-17 | Eingeleitet | Goldman | Neutral |
2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
2021-12-16 | Bestätigt | BofA Securities | Buy |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
2020-04-21 | Herabstufung | UBS | Buy → Neutral |
2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-05-28 | Eingeleitet | Goldman | Buy |
2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
2019-03-12 | Eingeleitet | JP Morgan | Overweight |
2019-01-23 | Eingeleitet | UBS | Buy |
2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-10-09 | Eingeleitet | Guggenheim | Buy |
2018-10-01 | Bestätigt | SunTrust | Buy |
2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Eli Lilly Teams With Laekna For Innovative Obesity Treatment - Finimize
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact with Chinese biotech for novel weight loss therapy - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch
Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com
Lilly announces changes on board of directors - Yahoo Finance
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86% - Yahoo Finance
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance
Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com
Cramer's Lightning Round: Eli Lilly is a buy - NECN
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):